Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

Sponsor

Children's Hospital of Philadelphia (Other)

Overall Status

Terminated

CT.gov ID

NCT03886753

Collaborator

Ilera Healthcare (Other)

Enrollment

Location

13.5

Actual Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an observational study of medical marijuana manufactured and dispensed by Ilera and given as standard treatment for a variety of approved serious medical conditions as defined by individual state law. All patients who are receiving one of the four formulations (Dream, Soothe, Shine and Ease) of medical marijuana will be provided a study flyer and asked to contact the study team via phone or email. Once the study team confirms eligibility, the study team will meet the subject face-to-face most likely at their dispensary (or other mutually agreeable location) and obtain informed consent, and assent when appropriate. Initial baseline demographic information, medical history and medication inventory will be completed. Also, since it is possible that the Investigators will enroll subjects across the region, Investigators anticipate the need to seek consent over the phone for many patients. This will be done via Skype, Go to Meeting, Facetime or similar platforms so that the Investigators can have a face to face interaction with the potential subjects. Regardless of where this discussion takes place (i.e., in person or via the web), all reasonable safeguards to ensure patient privacy will be taken. Patients or their legally authorized representative (LAR) will be given sufficient (i.e., up to several hours/days) to make a decision to participate in this study. Study staff will fax or email the consent form for their signature and no study procedures will begin until the signed consent form is received by the study team. The subjects or their LARs will be instructed on obtaining the blood samples. Blood draws will be completed in the subjects' home after one of their standard doses is taken.

Condition or Disease	Intervention/Treatment	Phase
ALS Autism Spectrum Disorder Cancer Spasticity, Muscle Dyskinetic Syndrome Epilepsy Glaucoma Huntington Disease Inflammatory Bowel Disease (IBD) Multiple Sclerosis Neuropathy Opioid Use Parkinson Disease HIV/AIDS Ptsd Intractable Pain Sickle Cell Disease Terminal Illness	Other: Registry Other: PK microsampling of blood

Detailed Description

This is a prospective PK/PD study that will include patients who are currently legally consuming one of the four medical marijuana formulations (Dream, Soothe, Shine and Ease) from Ilera Healthcare as part of their standard therapy for one of the state approved serious medical conditions.

Part 1 of the study consists of intake data of select subjects.

The patients will be identified at a dispensary that offers Ilera products.
Patients be given a flyer about the study by either study staff or dispensary staff.
Eligible patients will be asked to contact the study team if they are interested in the study.
If the patient is interested, a face-to-face (in person at the dispensary or in the patients home or other agreed upon location) consent/assent will be obtained.
Also, since it is possible that Investigators will enroll subjects across the region, Investigators anticipate the need to seek consent over the phone for many patients. This will be done via Skype, Go to Meeting, Facetime or similar platforms so that the investigators can have a face to face interaction with the potential subjects. Investigators will obtain written consent in all cases. Investigators will have them sign and fax or email/scan the signed consent form back to the study team.
Once consent is obtained demographic information will be collected as well as a medical and medication history and several questions related specifically to the medical marijuana product and its perceived effectiveness.
The data will be recorded in the REDCAP database. Part 2 of the study consists of pharmacokinetic evaluation of select subjects.
Parents/ care providers/ patients when appropriate will undergo education regarding PK sample acquisition
PK blood samples will be obtained and sent to the Children's Hospital of Philadelphia (CHOP) for determination of cannibidiol/ Tetrahydrocannabinol/ cannabinol (CBD/THC/CBN) concentrations
PK and PD analysis will occur

Study Design

Study Type:

Observational

Actual Enrollment :

10 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Pharmacokinetic and Pharmacodynamic Study of Ilera Medical Marijuana Products

Actual Study Start Date :

May 15, 2019

Actual Primary Completion Date :

Jun 30, 2020

Actual Study Completion Date :

Jun 30, 2020

Arms and Interventions

Arm	Intervention/Treatment
Ease Subjects using Ease as standard treatment. Registry and PK sampling	Other: Registry Collect data on subjects Other: PK microsampling of blood Obtain 5 microsamples of blood from subjects via a fingerstick.
Dream Subjects using Dream as standard treatment. Registry and PK sampling	Other: Registry Collect data on subjects Other: PK microsampling of blood Obtain 5 microsamples of blood from subjects via a fingerstick.
Soothe Subjects using Soothe as standard treatment. Registry and PK sampling	Other: Registry Collect data on subjects Other: PK microsampling of blood Obtain 5 microsamples of blood from subjects via a fingerstick.
Shine Those subjects using Shine as standard treatment. Registry and PK sampling	Other: Registry Collect data on subjects Other: PK microsampling of blood Obtain 5 microsamples of blood from subjects via a fingerstick.

Outcome Measures

Primary Outcome Measures

Change in symptoms [1 year]
Relief of primary indication (perceived therapeutic benefit of product)as reported by parent or caregiver on a 1-10 Lichert scale with 1 being minimally effective and 10 being extremely effective

Secondary Outcome Measures

Description and incidence of patient or caregiver reported side effects [1 year]
There is no particular instrument used in collecting this data. It is an open ended question where by patients and caregivers report possible side effects from the medical marijuana. Investigators will report the incidence in percentages.
Changes in drug concentrations [2 years]
The amount of a drug in a given volume of blood plasma, measured as the number of micrograms per milliliter
Rate of bioavailabilty [2 years]
The degree and rate at which the medication is absorbed by the body's circulatory system, the systemic circulation.
Volume of distribution [2 years]
The volume of medication that would be necessary to contain the total amount of the administered drug at the same concentration that it is observed in the blood plasma.
Report area under the plasma concentration versus time curve (AUC) [2 years]
The area under the curve (AUC) is the definite integral in a plot of drug concentration in blood plasma vs. time
Report half-life [2 years]
Half life is described as how long it takes for half of the dose to be metabolized and eliminated from the bloodstream.
Assess therapeutic range [2 years]
Comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity.

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Individuals who consume either Dream, Shine, Soothe or Ease medical marijuana manufactured by Ilera Heath care in a state which has legalized medical marijuana for state specified serious medical conditions.
Written informed consent and assent (if applicable)
Patients greater than 2 years of age

Exclusion Criteria:

Consumption of marijuana products that are not obtained from a state licensed dispensary
Non English speaking individuals
Have consumed a CBD/THC containing product other than the product under study within the 7 days prior to the PK study